India Pharma Sector Report FY26 H1 & Q2 FY26

Created by Piyush Patel_ in Economic Update Visit: 316 28 Nov 2025

Listen to this Blog

📊 Pharmaceuticals Industry Report – H1 & Q2 FY26

🌐 Industry Overview

Market Cap (Sector): ₹22,74,124 Cr
Sales: H1 ₹2,20,982 Cr (+10.9% YoY), Q2 ₹1,13,212 Cr (+13.3% YoY)
Profit: H1 ₹32,887 Cr (+4.2% YoY), Q2 ₹17,605 Cr (+10.6% YoY)
Margins: H1 14.9% (↓96 bps), Q2 15.6% (↓38 bps)

🏆 Market Cap Leaders

🏢 Company	💰 Market Cap (₹ Cr)	📈 Weight in Industry
🌞 Sun Pharma	4,28,074	18.8%
🔬 Divi’s Labs	1,66,993	7.3%
💊 Torrent Pharma	1,23,898	5.5%
🌿 Cipla	1,20,998	5.3%
🧪 Dr Reddy’s	1,01,392	4.5%
🧬 Zydus Life	92,882	4.1%
🌐 Lupin	91,684	4.0%
👨‍⚕️ Mankind	90,910	4.0%

➡️ Top 10 companies = ~49% of industry market cap.

📈 Growth Leaders (H1 FY26)

🔬 Laurus Labs: Sales +33%, Profit +980% 🚀
🌐 Lupin: Sales +18%, Profit +63% 💪
🔬 Divi’s Labs: Sales +15%, Profit +31% 🌟
🧬 Zydus Life: Sales +11%, Profit +17% 👍
💊 Torrent Pharma: Sales +13%, Profit +25% 📊

⚠️ Weakness: Sun Pharma (profit -8%), Mankind (profit -20%), Dr Reddy’s (flat profit).

⚡ Quarterly Momentum (Q2 FY26)

🔬 Laurus Labs: Profit +978% 🚀
🌐 Lupin: Profit +73% 💪
🧬 Zydus Life: Profit +38% 👍
🧪 Divi’s Labs: Profit +35% 🌟
🧪 Biocon: Profit +289% 🔄 rebound
💊 Glenmark: Sales +76%, Profit +72% ⚡

⚠️ Draggers: Mankind (profit -21%), Dr Reddy’s (profit -0.4%).

🧭 Weighted Impact (Investor Lens)

🌞 Sun Pharma: Largest weight, but weak profit leverage.
🔬 Divi’s Labs: Strong efficiency, margin expansion.
🌐 Lupin: Consistent compounding, strong leverage.
🔬 Laurus Labs: Dominates industry profit growth despite smaller size.
🧬 Zydus Life: Balanced growth + margin expansion.
🧪 Biocon: Turnaround in Q2, watch sustainability.

💡 Investor Recommendation

Core Quality Anchor: 🔬 Divi’s Labs (already held) – stable API/CDMO leader.
Growth Leverage: 🌐 Lupin – consistent compounding across H1 & Q2.
Turnaround Alpha: 🔬 Laurus Labs – extraordinary profit momentum.
Defensive Balance: 🏥 Abbott India / 💊 Alkem – steady margins, mid-teens growth.
Caution: 🌞 Sun Pharma (margin pressure), 👨‍⚕️ Mankind (profit decline), 🧪 Dr Reddy’s (flat earnings).

📌 Summary for Investors

Best Buy (with Divi’s Labs): 🌐 Lupin + 🔬 Laurus Labs
Balanced Portfolio: Divi’s (quality anchor) + Lupin (growth) + Laurus (turnaround)
Optional Defensive Add: Abbott India / Alkem for stability

Avoid Overweight: Sun Pharma, Mankind, Dr Reddy’s

Report Created By: Kinjal Bhatt

Disclosure:
This update is provided solely for informational purposes.
It does not constitute investment advice.
Readers should conduct their own research before making any investment decisions.